News | Biopsy Systems | July 17, 2017

Synergy Radiology Associates Employs UroNav Fusion Biopsy System for Better Prostate Cancer Diagnosis

System combines MRI, computer modeling and live ultrasound for faster, more accurate prostate cancer diagnosis after suspicious findings

Synergy Radiology Associates Employs UroNav Fusion Biopsy System for Better Prostate Cancer Diagnosis

July 17, 2017 — Radiologists from Synergy Radiology Associates (SRA) in Houston are using the power of 3-D medical imaging and subspecialty radiology to provide better patient care for men with suspicious prostate cancer findings.

The American Cancer Society reports that prostate cancer is the most common cancer and second leading cause of death among U.S. men. Therefore, when positive digital rectal exams (DRE) and elevated PSA (prostate-specific antigen) levels raise suspicion of cancer, a sampling (biopsy) of prostate gland tissue is recommended. These tissue samples are used to help diagnose and determine the grade, or Gleason score, of prostate cancer.

Unfortunately, current biopsy methods are not always efficient at finding actual cancer, leading to repeat and sometimes unnecessary biopsies. That’s where magnetic resonance imaging (MRI) and the UroNav Fusion Biopsy System come in.

“The UroNav approach tends to find those lesions that are more likely to become cancer and require treatment,” said SRA radiologist Larry Schock, M.D., specializing in body imaging and diagnostic radiology. “Radiologists appreciate the computer-aided 3-D imaging capabilities supporting UroNav that improve diagnosis, detection and treatment planning; our male patients appreciate a quicker, more certain diagnosis with fewer repeat or unnecessary biopsies. It’s also an excellent tool for diagnosing high-risk or aggressive prostate cancers.”

If a suspicious lesion is identified using prostate MRI, the UroNav DynaCAD workstation allows SRA radiologists to quickly view and work with 3-D images of the prostate for highly accurate diagnosis and location of suspicious tissue. Urologists then use live ultrasound plus existing 3-D MRI images during biopsy to obtain the best tissue samples.

Before UroNav, physicians relied primarily upon transrectal ultrasound (TRUS) to visualize the prostate gland and sample multiple areas of the prostate in an effort to detect possible cancer cells. However, with TRUS biopsies, cancer can often go undetected, according to recent published research.

“With UroNav, radiologists and urologists work in tandem, using the power of MRI, radiology subspecialty expertise and ultrasound guidance to accurately detect cancer 90 percent of the time,” said Schock. “This combined technology offers a truly new biopsy option for patients with suspicious prostate findings or who are under active surveillance.”

UroNav incorporates prostate image information from pre-biopsy MRI, computer-aided image enhancement and ultrasound-guided needle biopsy. This “fusion” of MRI and ultrasound results in targeted biopsies that are much better at detecting true cancer while avoiding the detection of low-risk or slow-growing cancer.

“Prostate is one of the most common but most curable cancers in men, and early, accurate detection can make all the difference in surviving,” said SRA President Walid Adham, M.D. “It’s incredibly rewarding for our radiology team to work with this advanced UroNav system to improve diagnosis, decrease worry and provide the best care possible to our patients.”

The UroNav fusion biopsy is an outpatient procedure that takes about 15 to 20 minutes and can be performed very shortly after the diagnostic MRI.

UroNav is recommended for patients with a PI-RADS (Prostate Imaging-Reporting and Data System) score of 3 or higher, negative prior TRUS biopsies with a continued elevated or rising PSA, or positive digital rectal examination with a negative TRUS biopsy.

For more information: www.invivocorp.com

Related Content

2018 Set to be Strong for the Global Ultrasound Market
Feature | Ultrasound Imaging | April 18, 2018 | Simon Harris
After a year of mixed fortunes, the global ultrasound market is set for a strong year in 2018.
Philips Integrates Reacts Tele-Ultrasound Platform on Lumify Portable Systems

Image courtesy of Philips Healthcare

News | Ultrasound Imaging | March 30, 2018
Philips in partnership with Innovative Imaging Technologies (IIT) announced an industry-first integrated tele-...
Clarius Initiates $200,000 Medical School Award Program
News | Ultrasound Imaging | March 30, 2018
Clarius Mobile Health is introducing its Clarius Medical School Award Program. Under that program, Clarius will grant...
Canon Receives FDA Approval for Ultrasound Liver Analysis Suite
Technology | Ultrasound Imaging | March 28, 2018
Canon Medical Systems USA Inc. received U.S. Food and Drug Administration (FDA) approval for a robust suite of...
Combination Radiotherapy Beneficial in Treating Prostate Cancer
News | Prostate Cancer | March 27, 2018
March 27, 2018 — While there are many treatment options for men with...
Samsung Unveils New RS85A Ultrasound System at AIUM 2018

The RS85A MV-Flow allows for visualization of slow-flow micro vascularized structures, which can be difficult to assess with conventional power Doppler ultrasound. Photo courtesy of Business Wire.

Technology | Ultrasound Imaging | March 26, 2018
Samsung NeuroLogica announced the Samsung RS85A ultrasound system has received U.S. Food and Drug Administration (FDA)...
Canon Aplio i600 Ultrasound System Receives FDA Clearance
Technology | Ultrasound Imaging | March 26, 2018
March 26, 2018 — Healthcare professionals seeking a cost-effective imaging solution without compromising image qualit
News | Ultrasound Imaging | March 21, 2018
Key processes in the body are controlled by the concentration of calcium in and around cells. A team from the Technical...
Overlay Init